Schering-Plough Announces FDA Approval of Saphris
From PR Newswire - Aug 14, 2009
KENILWORTH, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation today announced that the U.S. Food and Drug
Administration has approved Saphris (asenapine) sublingual tablets
for acute treatment of schizophrenia in adults and acute treatment of
manic or mixed episodes associated with bipolar I disorder with or
without psychotic features in adults.
www.peoplewho.org